BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.
Victor Sage
27 July 2026
Subscribe to Updates
Get moves for Bls Pharmaceuticals (ASX:BLS) direct to your inbox.
You're on the list!
We'll ping you the moment Bls Pharmaceuticals (ASX:BLS) makes a move.
Until then, follow us on socials.
Join 1000's of market focused, signal seeking investors. Unsubscribe anytime. We don't sell your data.